CEMIP and pancreatic neoplasm: Combined ROC curve analysis using CA 19-9 and CEMIP revealed an AUROC of 0.89 (95% CI: 0.862–0.920) with a sensitivity of 80.3% and a specificity of 97.9% in discriminating pancreatic cancer patients from normal individuals.